Clinical trial · Observational
Extended Treatment in Metastatic Breast Cancer With Eribulin
Long-term Eribulin Treatment in Metastatic Breast Cancer: A Multicenter, Case-study Analysis
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Decision-making for treatment of metastatic breast cancer after the second line of chemotherapy was limited by the lack of established predictive factors of benefit for further chemotherapy regimens. Eribulin has emerged as the only single agent demonstrating an overall survival improvement in the third-line setting or beyond. The purpose of this study was to define the clinical profile of metastatic breast cancer participants achieving long-term benefit from chemotherapy with eribulin in the third-line setting or beyond.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Participants treated with eribulin for at least 7 months
Primary outcomes (5)
- measure
- Overall survival
- timeFrame
- up to 7 months
- measure
- Progression free survival (PFS)
- timeFrame
- up to 7 months
- measure
- Objective response rate
- timeFrame
- up to 7 months
- measure
- Time to response
- timeFrame
- up to 7 months
- measure
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion criteria: * Participants with Advanced or Metastatic Breast Cancer on Eribulin for at least 7 months Exclusion criteria: * Lack of accessible clinical records
References
Publications (0)
Data not yet available